Gastroesophageal (GE) Junction Carcinomas Therapeutic Pipeline Review H1 2015 offers “Gastroesophageal (GE) Junction Carcinomas – Pipeline Review, H1 2015”global research report on its store.

This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report is available at .

Scope of The Report:

  • The report provides a snapshot of the global therapeutic landscape of Gastroesophageal (GE) Junction Carcinomas
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gastroesophageal (GE) Junction Carcinomas and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gastroesophageal (GE) Junction Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gastroesophageal (GE) Junction Carcinomas pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to Buy This Report:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Order a purchase copy of this report at .

Table of Content for “Gastroesophageal (GE) Junction Carcinomas – Pipeline Review, H1 2015” research report includes:

Gastroesophageal (GE) Junction Carcinomas Overview 8

Therapeutics Development 9

Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Overview 9

Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis 10

Gastroesophageal (GE) Junction Carcinomas - Therapeutics under Development by Companies 11

Gastroesophageal (GE) Junction Carcinomas - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Gastroesophageal (GE) Junction Carcinomas - Products under Development by Companies 15

Gastroesophageal (GE) Junction Carcinomas - Companies Involved in Therapeutics Development 16

Amgen Inc. 16

Aslan Pharmaceuticals Pte. Ltd. 17

AstraZeneca PLC 18

Basilea Pharmaceutica AG 19

Bristol-Myers Squibb Company 20

Celltrion, Inc. 21

Exelixis, Inc. 22

F. Hoffmann-La Roche Ltd. 23

Gilead Sciences, Inc. 24

Merck & Co., Inc. 25

Merck KGaA 26

Merrimack Pharmaceuticals, Inc. 27

Ono Pharmaceutical Co., Ltd. 28

Taiho Pharmaceutical Co., Ltd. 29

Gastroesophageal (GE) Junction Carcinomas - Therapeutics Assessment 30

Priced at US $2000 for a single user PDF, a discount on this research report can be requested at .

About Us:

RnR Market Research library offers syndicated reports by market research publishers from across the globe. We help you find the most relevant business intelligence from ready-to-buy syndicated market research studies. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more, RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest. ( .)